Last reviewed · How we verify

NCT07323043

Comparison of Cough Response Between Tegilidine and Sufentanil as Pre-induction Agents in General Anesthesia

Recruiting now NA Last updated 4 February 2026
What this trial tests

NA trial testing Tegilidine in General Anesthetic Drug Adverse Reaction in 190 participants. Currently enrolling.

Timeline
15 January 2026
Primary endpoint
16 May 2026
16 June 2026

Quick facts

Lead sponsorThe First People's Hospital of Lianyungang
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment190
Start date15 January 2026
Primary completion16 May 2026
Estimated completion16 June 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First People's Hospital of Lianyungang

Who can join

Adults 18 to 65, any sex, with General Anesthetic Drug Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In patients undergoing general anesthesia with planned tracheal intubation , a prospective, randomized, controlled, double-blind study was conducted to record the occurrence of cough 2 minutes after injection of Sufentanil or tegilidine. The cough was graded based on the frequency and duration: Grade I, no cough; Grade II, a single mild cough; Grade III, multiple coughs with duration \<1 second; Grade IV, continuous coughing with a duration \>15 seconds.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for General Anesthetic Drug Adverse Reaction

Currently open trials in the same condition.

Other The First People's Hospital of Lianyungang trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07323043.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing